1 ing higher doses initially, and intermittent pulse therapy.

2 py when inadequate responses are seen, or by pulse therapy.

3                       Treatment with steroid pulse therapy and high-dose intravenous immunoglobulin t

4 essitating further administration of steroid pulse therapy and IVCY.

5 piratory failure, treated again with steroid pulse therapy and IVCY.

6 roaches such as high-dose methylprednisolone pulse therapy are used to provide transient reductions i

7                                      Steroid pulse therapy followed by PSL 45 mg and immunosuppressiv

8  investigated the effect of cyclophosphamide pulse therapy in sensitized cardiac allograft recipients

9 gned a regimen consisting of intermittent or pulse therapy in which butyrate was administered for 4 d

10 was treated with a regimen including steroid pulse therapy, intravenous cyclophosphamide (IVCY), and

11 tment of cancer patients with 17-DMAG-based "pulse" therapy may improve the antitumor efficacy of CD8

12                                Dexamethasone pulse therapy reduced but did not eliminate the histolog

13 ts treated with intravenous cyclophosphamide pulse therapy together with intravenous immune globulin

14                           Therefore, steroid pulse therapy using intravenous administration of methyl

15 fect in the eyes were also observed, steroid pulse therapy was administered early in the course of th

16  the time of transplant; those given steroid pulse therapy were at exceptionally high-risk.

17                                              Pulse therapy with anti-CD3 plus anti-TNF was found to i

18  < 0.001) that were significantly reduced by pulse therapy with dexamethasone for 2 days prior to ani

19                                 Intermittent pulse therapy with low doses of select COX-2 inhibitors